GD
59
2
AKAM
64
2
SE
47
-5
CTSH
63
3
TMO
60
2
AEP
64
-3
SHW
59
3
IFF
60
-6
GILD
52
2
CRM
52
2
RIG
57
3
YUM
52
2
MAT
56
6
AAL
56
5
AES
45
-4
HOG
45
3
BDX
61
2
PAYX
45
7
MS
76
3
CVS
39
-4
GD
59
2
AKAM
64
2
SE
47
-5
CTSH
63
3
TMO
60
2
AEP
64
-3
SHW
59
3
IFF
60
-6
GILD
52
2
CRM
52
2
RIG
57
3
YUM
52
2
MAT
56
6
AAL
56
5
AES
45
-4
HOG
45
3
BDX
61
2
PAYX
45
7
MS
76
3
CVS
39
-4
Financhill
Back

Monte Rosa Therapeutics, Inc. 10K Form

Buy
69

GLUE
Monte Rosa Therapeutics, Inc.

Last Price:
$17.24
Seasonality Move:
6.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive GLUE News And Ratings

See the #1 stock for the next 7 days that we like better than GLUE

GLUE Financial Statistics

Sales & Book Value

Annual Sales: $75.6M
Cash Flow: $99.8M
Price / Cash Flow: 8.98
Annual Sales: $3.98
Price / Book: 4.47

Profitability

EPS (TTM): 0.30540
Net Income (TTM): $20.9M
Gross Margin: $67.5M
Return on Equity: 8.6%
Return on Assets: 5.33%

Monte Rosa Therapeutics, Inc. Earnings Forecast

Key Monte Rosa Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 6 years for GLUE is 89.26%.
  • The Selling, General & Administrative Expenses for GLUE have been equal to 46.51% of Gross Profit Margin.
  • The Research & Development expenses have been 150.01% of Revenue.
  • The Net Earning history of GLUE is -96.14% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 1 years.

Monte Rosa Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: GLUE
Website: monterosatx.com

Debt

Debt-to-Equity Ratio: 0.16
Current Ratio: 6.54
Quick Ratio: 6.37

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

GLUE Technical Analysis vs Fundamental Analysis

Buy
69
Monte Rosa Therapeutics, Inc. (GLUE) is a Buy

Is Monte Rosa Therapeutics, Inc. a Buy or a Sell?